Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1887267 | 0.80 | PDE5A (0.56) | PDE5APDE6C | |
| SCHEMBL6412001 | 0.77 | KDM4E (0.36) | PDE5A | |
| SCHEMBL5023679 | 0.71 | PDE5A (0.73) | PDE5A | |
| SCHEMBL6408971 | 0.71 | PDE5A (0.73) | PDE5A | |
| SCHEMBL6407697 | 0.71 | PDE5A (0.67) | PDE5A | |
| SCHEMBL5530176 | 0.71 | PDE5A (0.67) | PDE5A | |
| SCHEMBL6406535 | 0.69 | SMN1; SMN2 (0.57) | PDE5A | |
| SCHEMBL14629722 | 0.66 | PDE5A (0.40) | PDE5APDE6C | |
| SCHEMBL6408372 | 0.65 | PDE5A (0.70) | PDE5A | |
| SCHEMBL14629720 | 0.59 | ADRA1D (0.52) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050113402-A1 | Substituted pyrrolopyridinone derivatives useful as phosphodiesterase inhibitors | SUI ZHIHUA (US) | 2005-05-26 | — | — | US | disclosed |
| US-6818646-B2 | 1,2,3,4-TETRAHYDRO-2-(5-(2-PYRIDINYL)-PYRIMIDIN-2-YL)-3-(2,3 -DIHYDROBENZOFURANYL)-9H-PYRROLO-(3,4-B)QUINOLIN-9-ONE; MALE ERECTILE DYSFUNCTION; SEXUAL DISORDERS | SUI ZHIHUA (US) | 2004-11-16 | — | — | US | disclosed |
| US-20040044021-A1 | Substituted pyrrolopyridinone derivatives useful as phosphodiesterase inhibitors | SUI ZHIHUA (US) | 2004-03-04 | — | — | US | disclosed |
| US-6635638-B2 | Treatment of sexual dysfunction, cardiovascular system disorders | ORTHO-MCNEIL PHARMACEUTICAL, INC. | 2003-10-21 | — | — | US | disclosed |
| US-20020010183-A1 | Substituted pyrrolopyridinone derivatives useful as phosphodiesterase inhibitors | ORTHO-MCNEIL PHARMACEUTICAL, INC. | 2002-01-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050113402-A1 | Substituted pyrrolopyridinone derivatives useful as phosphodiesterase inhibitors | PDE5A, PDE3A, PDE3B | PDE5A 1/4885PDE6C 31/4885 |
| US-20040044021-A1 | Substituted pyrrolopyridinone derivatives useful as phosphodiesterase inhibitors | PDE5A, PDE3A, PDE3B | PDE5A 1/4885PDE6C 30/4885 |
| US-20020010183-A1 | Substituted pyrrolopyridinone derivatives useful as phosphodiesterase inhibitors | PDE5A, PDE3A, PDE3B | PDE5A 1/4885PDE6C 30/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.